2020
Pregnancy outcomes and risk of endometrial cancer: A pooled analysis of individual participant data in the Epidemiology of Endometrial Cancer Consortium
Jordan SJ, Na R, Weiderpass E, Adami H, Anderson KE, van den Brandt P, Brinton LA, Chen C, Cook LS, Doherty JA, Du M, Friedenreich CM, Gierach GL, Goodman MT, Krogh V, Levi F, Lu L, Miller AB, McCann SE, Moysich KB, Negri E, Olson SH, Petruzella S, Palmer JR, Parazzini F, Pike MC, Prizment AE, Rebbeck TR, Reynolds P, Ricceri F, Risch HA, Rohan TE, Sacerdote C, Schouten LJ, Serraino D, Setiawan VW, Shu X, Sponholtz TR, Spurdle AB, Stolzenberg‐Solomon R, Trabert B, Wentzensen N, Wilkens LR, Wise LA, Yu H, La Vecchia C, De Vivo I, Xu W, Zeleniuch‐Jacquotte A, Webb PM. Pregnancy outcomes and risk of endometrial cancer: A pooled analysis of individual participant data in the Epidemiology of Endometrial Cancer Consortium. International Journal Of Cancer 2020, 148: 2068-2078. PMID: 33105052, PMCID: PMC7969437, DOI: 10.1002/ijc.33360.Peer-Reviewed Original ResearchConceptsEndometrial cancer riskFull-term pregnancyLast full-term pregnancyEndometrial Cancer ConsortiumCancer riskEndometrial cancerIndividual participant dataIncomplete pregnanciesPooled analysisAdditional pregnanciesOdds ratioCancer ConsortiumFirst full-term pregnancyParticipant dataPregnancy-related factorsPooled odds ratioCase-control studyHigh progesterone levelsRisk reductionLast pregnancyPregnancy outcomesSingleton pregnanciesControl womenLast trimesterProgesterone levelsMendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer
Kho P, Amant F, Annibali D, Ashton K, Attia J, Auer PL, Beckmann MW, Black A, Brinton L, Buchanan DD, Chanock SJ, Chen C, Chen MM, Cheng THT, Cook LS, Crous‐Bous M, Czene K, De Vivo I, Dennis J, Dörk T, Dowdy SC, Dunning AM, Dürst M, Easton DF, Ekici AB, Fasching PA, Fridley BL, Friedenreich CM, García‐Closas M, Gaudet MM, Giles GG, Goode EL, Gorman M, Haiman CA, Hall P, Hankinson SE, Hein A, Hillemanns P, Hodgson S, Hoivik EA, Holliday EG, Hunter DJ, Jones A, Kraft P, Krakstad C, Lambrechts D, Le Marchand L, Liang X, Lindblom A, Lissowska J, Long J, Lu L, Magliocco AM, Martin L, McEvoy M, Milne RL, Mints M, Nassir R, Otton G, Palles C, Pooler L, Proietto T, Rebbeck TR, Renner SP, Risch HA, Rübner M, Runnebaum I, Sacerdote C, Sarto GE, Schumacher F, Scott RJ, Setiawan VW, Shah M, Sheng X, Shu X, Southey MC, Tham E, Tomlinson I, Trovik J, Turman C, Tyrer JP, Van Den Berg D, Wang Z, Wentzensen N, Xia L, Xiang Y, Yang HP, Yu H, Zheng W, Webb PM, Thompson DJ, Spurdle AB, Glubb DM, O'Mara TA. Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer. International Journal Of Cancer 2020, 148: 307-319. PMID: 32851660, PMCID: PMC7757859, DOI: 10.1002/ijc.33206.Peer-Reviewed Original ResearchConceptsNon-endometrioid endometrial cancerEndometrial cancer riskEndometrial cancerLDL cholesterol levelsMendelian randomization analysisBlood lipidsCholesterol levelsCancer riskRandomization analysisLower endometrial cancer riskNon-endometrioid subtypesHDL cholesterol levelsBlood lipid levelsEndometrial cancer developmentRange of cancersTwo-sample Mendelian randomization (MR) analysisPotential confounding roleHDL cholesterolColorectal cancerLipid levelsObservational studyLower riskGlobal Lipids Genetics ConsortiumCancerInconsistent associations
2018
Randomized controlled trial of weight loss versus usual care on telomere length in women with breast cancer: the lifestyle, exercise, and nutrition (LEAN) study
Sanft T, Usiskin I, Harrigan M, Cartmel B, Lu L, Li FY, Zhou Y, Chagpar A, Ferrucci LM, Pusztai L, Irwin ML. Randomized controlled trial of weight loss versus usual care on telomere length in women with breast cancer: the lifestyle, exercise, and nutrition (LEAN) study. Breast Cancer Research And Treatment 2018, 172: 105-112. PMID: 30062572, DOI: 10.1007/s10549-018-4895-7.Peer-Reviewed Original ResearchConceptsBreast cancer survivorsWeight loss interventionUsual care groupBody mass indexBreast cancer riskCancer survivorsUsual careLoss interventionBreast cancerStage 0Quantitative polymerase chain reactionCare groupTelomere lengthCancer riskStage II/III breast cancerObese breast cancer survivorsWeight lossI breast cancerNon-Hispanic whitesPurposeSome studiesMass indexIntervention groupPhysical activityBlood samplesConclusionOur findings
2017
Breastfeeding and Endometrial Cancer Risk
Jordan SJ, Na R, Johnatty SE, Wise LA, Adami HO, Brinton LA, Chen C, Cook LS, Dal Maso L, De Vivo I, Freudenheim JL, Friedenreich CM, La Vecchia C, McCann SE, Moysich KB, Lu L, Olson SH, Palmer JR, Petruzella S, Pike MC, Rebbeck TR, Ricceri F, Risch HA, Sacerdote C, Setiawan VW, Sponholtz TR, Shu XO, Spurdle AB, Weiderpass E, Wentzensen N, Yang HP, Yu H, Webb PM. Breastfeeding and Endometrial Cancer Risk. Obstetrics And Gynecology 2017, 129: 1059-1067. PMID: 28486362, PMCID: PMC5473170, DOI: 10.1097/aog.0000000000002057.Peer-Reviewed Original ResearchConceptsEndometrial cancer riskEndometrial cancerCancer riskOdds ratioStudy-specific odds ratiosEndometrial Cancer ConsortiumBody mass indexMultivariable logistic regressionConfidence intervalsCase-control studyMaternal benefitsNulliparous womenHistologic subtypeMass indexCommon cancerLower riskStudy heterogeneityCancer ConsortiumControl groupCancerLogistic regressionAverage durationLonger average durationWomenBreastfeedingEnvironmental factors, seven GWAS‐identified susceptibility loci, and risk of gastric cancer and its precursors in a Chinese population
Cai M, Dai S, Chen W, Xia C, Lu L, Dai S, Qi J, Wang M, Wang M, Zhou L, Lei F, Zuo T, Zeng H, Zhao X. Environmental factors, seven GWAS‐identified susceptibility loci, and risk of gastric cancer and its precursors in a Chinese population. Cancer Medicine 2017, 6: 708-720. PMID: 28220687, PMCID: PMC5345626, DOI: 10.1002/cam4.1038.Peer-Reviewed Original ResearchMeSH KeywordsAlcohol DrinkingAMP-Activated Protein KinasesAntigens, NeoplasmAsian PeopleChinaFemaleGenetic Predisposition to DiseaseGenome-Wide Association StudyGPI-Linked ProteinsHelicobacter InfectionsHumansLogistic ModelsMaleMembrane Transport ProteinsMucin-1Neoplasm ProteinsNerve Tissue ProteinsRisk FactorsSmokingStomach NeoplasmsTranscription FactorsConceptsRisk of GCPylori infectionAlcohol drinkingPRKAA1 rs13361707Intestinal metaplasiaGastric cancerGene-environment interactionsGastric carcinogenesisChinese populationSevere intestinal metaplasiaHelicobacter pylori infectionUnconditional logistic regressionPrecancerous gastric lesionsGastric cancer riskEnvironmental risk factorsGenetic predisposition factorsGenome-wide association studiesSusceptibility lociMUC1 rs4072037Gastric lesionsRisk factorsEffect modificationCancer riskAlcohol consumptionDisease risk
2015
Body Mass Index Genetic Risk Score and Endometrial Cancer Risk
Prescott J, Setiawan VW, Wentzensen N, Schumacher F, Yu H, Delahanty R, Bernstein L, Chanock SJ, Chen C, Cook LS, Friedenreich C, Garcia-Closas M, Haiman CA, Le Marchand L, Liang X, Lissowska J, Lu L, Magliocco AM, Olson SH, Risch HA, Shu XO, Ursin G, Yang HP, Kraft P, De Vivo I. Body Mass Index Genetic Risk Score and Endometrial Cancer Risk. PLOS ONE 2015, 10: e0143256. PMID: 26606540, PMCID: PMC4659592, DOI: 10.1371/journal.pone.0143256.Peer-Reviewed Original ResearchConceptsEndometrial cancer riskBody mass indexGenotype risk scoreCancer riskRisk scoreHigher body mass indexRisk allelesIndependent risk factorEndometrial cancer casesExcess body weightRisk factor dataGenetic risk scoreGenome-wide association studiesEndometrial cancerMass indexBMI riskRisk factorsEffect modificationCancer casesRisk lociBody weightCancer shareExploratory analysisStudy designControl participantsJoint Effect of Genotypic and Phenotypic Features of Reproductive Factors on Endometrial Cancer Risk
Wang Z, Risch H, Lu L, Irwin ML, Mayne S, Schwartz P, Rutherford T, De Vivo I, Yu H. Joint Effect of Genotypic and Phenotypic Features of Reproductive Factors on Endometrial Cancer Risk. Scientific Reports 2015, 5: 15582. PMID: 26498156, PMCID: PMC4620445, DOI: 10.1038/srep15582.Peer-Reviewed Original ResearchConceptsEndometrial cancer riskEndometrial cancerCancer riskEstrogen exposureEndometrial cancer patientsTime of studyGenetic risk scorePotential confoundersCancer patientsMenstrual cycleReproductive factorsRisk scorePossible markerMajor causeCancerMenopauseObesityPhenotypic featuresRiskPopulation controlsAgeMenarcheWomenExposureTNMCVitamin D and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Case–Control Consortium
Waterhouse M, Risch HA, Bosetti C, Anderson KE, Petersen GM, Bamlet WR, Cotterchio M, Cleary SP, Ibiebele TI, La Vecchia C, Skinner HG, Strayer L, Bracci PM, Maisonneuve P, Bueno-de-Mesquita HB, Zaton Ski W, Lu L, Yu H, Janik-Koncewicz K, Polesel J, Serraino D, Neale RE. Vitamin D and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Case–Control Consortium. Annals Of Oncology 2015, 26: 1776-1783. PMID: 25977560, PMCID: PMC4511221, DOI: 10.1093/annonc/mdv236.Peer-Reviewed Original ResearchConceptsVitamin D intakeDietary vitamin D intakePancreatic Cancer Case-Control ConsortiumPancreatic cancerD intakeVitamin DOdds ratioInternational Pancreatic Cancer Case-Control ConsortiumStudy-specific odds ratiosTotal vitamin D intakeMultivariable logistic regressionCase-control studyPancreatic cancer riskRandom-effects modelEstimates of associationDietary intakeCancer riskLogistic regressionCancerIntakeAdditional studiesPotential roleAssociationRiskNegative associationInfertility and incident endometrial cancer risk: a pooled analysis from the epidemiology of endometrial cancer consortium (E2C2)
Yang HP, Cook LS, Weiderpass E, Adami HO, Anderson KE, Cai H, Cerhan JR, Clendenen TV, Felix AS, Friedenreich CM, Garcia-Closas M, Goodman MT, Liang X, Lissowska J, Lu L, Magliocco AM, McCann SE, Moysich KB, Olson SH, Petruzella S, Pike MC, Polidoro S, Ricceri F, Risch HA, Sacerdote C, Setiawan VW, Shu XO, Spurdle AB, Trabert B, Webb PM, Wentzensen N, Xiang YB, Xu Y, Yu H, Zeleniuch-Jacquotte A, Brinton LA. Infertility and incident endometrial cancer risk: a pooled analysis from the epidemiology of endometrial cancer consortium (E2C2). British Journal Of Cancer 2015, 112: 925-933. PMID: 25688738, PMCID: PMC4453954, DOI: 10.1038/bjc.2015.24.Peer-Reviewed Original ResearchConceptsEndometrial cancer riskCancer riskInfertility causesOdds ratioElevated endometrial cancer riskEndometrial cancer risk factorsEndometrial Cancer ConsortiumSelf-reported infertilityAdjusted odds ratioCancer risk factorsConfidence intervalsCase-control studyStudy-specific definitionsParous womenEndometrial cancerNulliparous womenPooled analysisNational registryRisk factorsCancer ConsortiumInfertilityNulliparityInfertility concernsInfertility dataLarger study
2014
Intrauterine devices and endometrial cancer risk: A pooled analysis of the Epidemiology of Endometrial Cancer Consortium
Felix AS, Gaudet MM, La Vecchia C, Nagle CM, Shu XO, Weiderpass E, Adami HO, Beresford S, Bernstein L, Chen C, Cook LS, De Vivo I, Doherty JA, Friedenreich CM, Gapstur SM, Hill D, Horn‐Ross P, Lacey JV, Levi F, Liang X, Lu L, Magliocco A, McCann SE, Negri E, Olson SH, Palmer JR, Patel AV, Petruzella S, Prescott J, Risch HA, Rosenberg L, Sherman ME, Spurdle AB, Webb PM, Wise LA, Xiang Y, Xu W, Yang HP, Yu H, Zeleniuch‐Jacquotte A, Brinton LA. Intrauterine devices and endometrial cancer risk: A pooled analysis of the Epidemiology of Endometrial Cancer Consortium. International Journal Of Cancer 2014, 136: e410-e422. PMID: 25242594, PMCID: PMC4267918, DOI: 10.1002/ijc.29229.Peer-Reviewed Original ResearchConceptsEndometrial Cancer ConsortiumEndometrial cancer riskIntrauterine deviceEC riskPooled analysisCancer riskLast useCancer ConsortiumOlder ageUse of IUDsMultivariable logistic regressionConfidence intervalsPooled odds ratioCase-control studyInert intrauterine deviceDuration of useHeavy bleedingOdds ratioReversible contraceptivesHormonal changesEC casesReduced riskBiologic effectsUterine environmentLogistic regressionCross-cancer pleiotropic analysis of endometrial cancer: PAGE and E2C2 consortia
Setiawan VW, Schumacher F, Prescott J, Haessler J, Malinowski J, Wentzensen N, Yang H, Chanock S, Brinton L, Hartge P, Lissowska J, Park SL, Cheng I, Bush WS, Crawford DC, Ursin G, Horn-Ross P, Bernstein L, Lu L, Risch H, Yu H, Sakoda LC, Doherty J, Chen C, Jackson R, Yasmeen S, Cote M, Kocarnik JM, Peters U, Kraft P, De Vivo I, Haiman CA, Kooperberg C, Le Marchand L. Cross-cancer pleiotropic analysis of endometrial cancer: PAGE and E2C2 consortia. Carcinogenesis 2014, 35: 2068-2073. PMID: 24832084, PMCID: PMC4146418, DOI: 10.1093/carcin/bgu107.Peer-Reviewed Original ResearchConceptsEndometrial cancer riskEndometrial cancerCancer riskSingle nucleotide polymorphismsEndometrial Cancer ConsortiumEndometrial cancer casesBody mass indexProstate cancer riskMultiple cancer sitesEvidence of heterogeneityMass indexCancer sitesProstate cancerBonferroni-corrected P valueCancer casesCancer-associated single nucleotide polymorphismsCancer ConsortiumGenome-wide association studiesCancerStatistical significanceP-valueEpidemiologyRiskBiological mechanismsEuropean ancestryThe KRAS-Variant and miRNA Expression in RTOG Endometrial Cancer Clinical Trials 9708 and 9905
Lee LJ, Ratner E, Uduman M, Winter K, Boeke M, Greven KM, King S, Burke TW, Underhill K, Kim H, Boulware RJ, Yu H, Parkash V, Lu L, Gaffney D, Dicker AP, Weidhaas J. The KRAS-Variant and miRNA Expression in RTOG Endometrial Cancer Clinical Trials 9708 and 9905. PLOS ONE 2014, 9: e94167. PMID: 24732316, PMCID: PMC3986055, DOI: 10.1371/journal.pone.0094167.Peer-Reviewed Original ResearchConceptsEndometrial cancer riskType 2 endometrial cancerEndometrial cancerKRAS-variantCancer riskLymphovascular invasionSurvival outcomesTumor biologyType 1 endometrial cancerEndometrial cancer trialsOverall survival rateMiRNA expressionAge-matched controlsCase-control analysisFunctional germline variantsClinical characteristicsPatient ageTumor characteristicsCancer trialsTumor specimensSurvival rateType 1Germline variantsMiRNA expression levelsCancer
2013
Polymorphisms in Inflammation Pathway Genes and Endometrial Cancer Risk
Delahanty RJ, Xiang YB, Spurdle A, Beeghly-Fadiel A, Long J, Thompson D, Tomlinson I, Yu H, Lambrechts D, Dörk T, Goodman MT, Zheng Y, Salvesen HB, Bao PP, Amant F, Beckmann MW, Coenegrachts L, Coosemans A, Dubrowinskaja N, Dunning A, Runnebaum IB, Easton D, Ekici AB, Fasching PA, Halle MK, Hein A, Howarth K, Gorman M, Kaydarova D, Krakstad C, Lose F, Lu L, Lurie G, O'Mara T, Matsuno RK, Pharoah P, Risch H, Corssen M, Trovik J, Turmanov N, Wen W, Lu W, Cai Q, Zheng W, Shu XO. Polymorphisms in Inflammation Pathway Genes and Endometrial Cancer Risk. Cancer Epidemiology Biomarkers & Prevention 2013, 22: 216-223. PMID: 23221126, PMCID: PMC3677562, DOI: 10.1158/1055-9965.epi-12-0903.Peer-Reviewed Original ResearchMeSH KeywordsAsian PeopleBiomarkers, TumorCase-Control StudiesChinaEndometrial NeoplasmsFemaleFollow-Up StudiesGene Expression ProfilingGenetic Predisposition to DiseaseHumansInflammationLinkage DisequilibriumMiddle AgedNeoplasm StagingOligonucleotide Array Sequence AnalysisPolymorphism, Single NucleotidePrognosisRisk FactorsConceptsEndometrial cancer riskEndometrial cancer casesEndometrial cancerSingle nucleotide polymorphismsOdds ratioCancer casesEndometrial carcinogenesisCancer riskStage IConfidence intervalsInflammation pathway genesInflammatory pathway genesAllelic odds ratioChronic inflammationEpidemiologic evidenceInflammatory pathwaysPathway genesSignificant associationStage IIGenetic susceptibilityMMP9 polymorphismsAdditional studiesCancerGenetic polymorphismsFollow-up genotyping
2012
Omega-3 and omega-6 fatty acid intakes and endometrial cancer risk in a population-based case–control study
Arem H, Neuhouser ML, Irwin ML, Cartmel B, Lu L, Risch H, Mayne ST, Yu H. Omega-3 and omega-6 fatty acid intakes and endometrial cancer risk in a population-based case–control study. European Journal Of Nutrition 2012, 52: 1251-1260. PMID: 22915050, PMCID: PMC3548981, DOI: 10.1007/s00394-012-0436-z.Peer-Reviewed Original ResearchConceptsEndometrial cancer riskFatty acid intakeCancer riskEndometrial cancerAcid intakeDietary intakePopulation-based case-control studyFish oil supplement useUnconditional logistic regression methodsLong-chain omega-3 fatty acidsOmega-3 fatty acidsIncident cancer casesCase-control studyAge-matched controlsFatty acidsPopulation-based sampleTotal fish intakeSupplement useFish intakeExtreme quartilesProtective associationCancer casesHigh intakeReduced riskFatty acids EPAAge at Last Birth in Relation to Risk of Endometrial Cancer: Pooled Analysis in the Epidemiology of Endometrial Cancer Consortium
Setiawan VW, Pike MC, Karageorgi S, Deming SL, Anderson K, Bernstein L, Brinton LA, Cai H, Cerhan JR, Cozen W, Chen C, Doherty J, Freudenheim JL, Goodman MT, Hankinson SE, Lacey JV, Liang X, Lissowska J, Lu L, Lurie G, Mack T, Matsuno RK, McCann S, Moysich KB, Olson SH, Rastogi R, Rebbeck TR, Risch H, Robien K, Schairer C, Shu XO, Spurdle AB, Strom BL, Thompson PJ, Ursin G, Webb PM, Weiss NS, Wentzensen N, Xiang YB, Yang HP, Yu H, Horn-Ross PL, De Vivo I, Group T. Age at Last Birth in Relation to Risk of Endometrial Cancer: Pooled Analysis in the Epidemiology of Endometrial Cancer Consortium. American Journal Of Epidemiology 2012, 176: 269-278. PMID: 22831825, PMCID: PMC3491967, DOI: 10.1093/aje/kws129.Peer-Reviewed Original ResearchConceptsEndometrial Cancer ConsortiumEndometrial cancerLast birthCancer ConsortiumLarge pooled analysisTumor histologic subtypeEndometrial cancer riskExogenous hormone useBody mass indexPooled odds ratioCase-control studyYears of ageHormone useHistologic subtypeMass indexPooled analysisRisk factorsEffect modificationOdds ratioDiagnosis groupsProtective associationCancer riskLower riskNumber of birthsOlder age
2011
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer
Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S, Muller RU, Bignotti E, Bellone S, Boeke M, Yao X, Pecorelli S, Ravaggi A, Katsaros D, Zelterman D, Cristea MC, Yu H, Rutherford TJ, Weitzel JN, Neuhausen SL, Schwartz PE, Slack FJ, Santin AD, Weidhaas JB. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene 2011, 31: 4559-4566. PMID: 22139083, PMCID: PMC3342446, DOI: 10.1038/onc.2011.539.Peer-Reviewed Original ResearchMeSH Keywords3' Untranslated RegionsAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBRCA1 ProteinBRCA2 ProteinCarboplatinCell Line, TumorCell SurvivalDrug Resistance, NeoplasmFemaleGenotypeHumansKaplan-Meier EstimateMiddle AgedMultivariate AnalysisMutationNeoplasms, Glandular and EpithelialOvarian NeoplasmsPaclitaxelPolymorphism, Single NucleotidePrognosisProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)Ras ProteinsRNA InterferenceTreatment OutcomeConceptsEpithelial ovarian cancerEOC patientsKRAS-variantOvarian cancerPoor outcomeCancer riskTumor biologyPlatinum resistanceComplete clinical dataBiomarkers of outcomeDirect targetingEOC cell growthKnown BRCA mutationsFuture treatment approachesSubset of tumorsPlatinum chemotherapy resistanceCell linesNeoadjuvant chemotherapyBRCA mutationsClinical dataTreatment approachesChemotherapy resistanceKRAS oncogeneMultivariate analysisPatientsRisk of second primary cancer after treatment for esophageal cancer: a pooled analysis of nine cancer registries
Zhu G, Chen Y, Zhu Z, Lu L, Bi X, Deng Q, Chen X, Su H, Liu Y, Guo H, Zheng T, Yu H, Zhang Y. Risk of second primary cancer after treatment for esophageal cancer: a pooled analysis of nine cancer registries. Diseases Of The Esophagus 2011, 25: 505-511. PMID: 22067063, DOI: 10.1111/j.1442-2050.2011.01273.x.Peer-Reviewed Original ResearchConceptsStandardized incidence ratiosEsophageal cancer survivorsSecond primary cancerSecond cancersEsophageal cancerPrimary cancerCancer survivorsProstate cancerCancer riskEnd Results ProgramEsophageal cancer patientsAssociation of radiotherapySecond cancer riskMost risk estimatesCancer RegistryIncidence ratiosDecreased riskPatient survivalResults ProgramPooled analysisCancer patientsLung cancerClinical trialsSecondary cancersGeneral populationLong‐term overweight and weight gain in early adulthood in association with risk of endometrial cancer
Lu L, Risch H, Irwin ML, Mayne ST, Cartmel B, Schwartz P, Rutherford T, Yu H. Long‐term overweight and weight gain in early adulthood in association with risk of endometrial cancer. International Journal Of Cancer 2011, 129: 1237-1243. PMID: 21387312, PMCID: PMC3125463, DOI: 10.1002/ijc.26046.Peer-Reviewed Original ResearchConceptsBody mass indexLong-term overweightEndometrial cancerSubstantial weight gainWeight gainBody weightPopulation-based case-control studyHigher body mass indexEndometrial cancer riskWeight changeDisease 10 yearsEarly adulthoodUnconditional logistic regressionAdult lifeCase-control studyTime of interviewSuch weight changesMass indexNormal weightIncident casesRisk factorsOdds ratioLong-term effectsAge 40Cancer risk
2010
Physical activity and endometrial cancer in a population-based case–control study
Arem H, Irwin ML, Zhou Y, Lu L, Risch H, Yu H. Physical activity and endometrial cancer in a population-based case–control study. Cancer Causes & Control 2010, 22: 219-226. PMID: 21110224, PMCID: PMC3075067, DOI: 10.1007/s10552-010-9689-0.Peer-Reviewed Original ResearchConceptsEndometrial cancer riskLower endometrial cancer riskMET h/wkPhysical activityCancer riskEndometrial cancerRisk factorsPopulation-based case-control studyInterview-administered questionnaireMetabolic equivalent hoursPhysical Activity QuestionnaireUnconditional logistic regressionRecreational physical activityCase-control studyAge-matched controlsPhysical activity dataIncident casesActivity QuestionnaireIndependent associationConclusionOur dataLifestyle informationBMILogistic regressionReference groupCancerA KRAS-Variant in Ovarian Cancer Acts as a Genetic Marker of Cancer Risk
Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, Pelletier C, Blitzblau R, Tassi R, Paranjape T, Hui P, Godwin AK, Yu H, Risch H, Rutherford T, Schwartz P, Santin A, Matloff E, Zelterman D, Slack FJ, Weidhaas JB. A KRAS-Variant in Ovarian Cancer Acts as a Genetic Marker of Cancer Risk. Cancer Research 2010, 70: 6509-6515. PMID: 20647319, PMCID: PMC2923587, DOI: 10.1158/0008-5472.can-10-0689.Peer-Reviewed Original ResearchConceptsOvarian cancerKRAS-variantOC patientsCancer riskRisk of OCIndependent case-control analysesCase-control studyOvarian cancer syndromeCase-control analysisFamily membersAdvanced diseaseWomen's cancersRisk factorsBRCA2 mutationsHBOC patientsOC casesIndependent cohortHBOC familiesHereditary breastSolid tumorsCancer syndromesKRAS oncogeneVariant allelesPatientsCancer